RE:NEWS ....... JUVAF is a vertically integrated medical and recreational cannabis company. Juva Cultivation, Juva Research, Juva Retail, and Juva Delivery are the segments under which it operates. JUVAF ended Friday’s trading session at $1.03, gaining 5.4% over the past year. JUVAF aims to be a pioneer in creating “cannabis therapeutic” data for medical cannabis market in the United States.
The company started its operations in 2019 and has unique offerings but it is still in its nascent stages. Hence, there is a lot of ambiguity about its prospects in the near term.
JUVAF’s uncertain prospects are reflected in its POWR Ratings. The stock has an overall rating of C, which equates to Neutral in our proprietary rating system. It has a C for Growth, Stability, and Sentiment. It is ranked #124 in the Medical – Pharmaceuticals industry.
In total, we rate JUVAF on eight different levels. Beyond what we stated above we also have given JUVAF grades for Value, Momentum, and Quality. Get all the JUVAF ratings here.
The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.